ASCO will highlight a wave of pancreatic cancer innovation beyond KRAS, with daraxonrasib’s new data expected to anchor attention. Abstract coverage also points to multiple mechanism classes, including antibody-drug conjugates, bispecifics, and diagnostics aimed at improving patient selection and outcomes. The focus on post-KRAS strategies underscores how companies are reframing clinical development around actionable biology rather than single-pathway dependence. For investors and trial operators, the meeting preview signals where near-term trial readouts and competitive differentiation could concentrate. The 2026 agenda also suggests a broader trial design push—pairing targeted agents with biomarker-enriched populations and companion diagnostics—consistent with how pancreatic programs are increasingly structured.